Prediction of stillbirth from placental growth factor at 19-24 weeks.

نویسندگان

  • J E Aupont
  • R Akolekar
  • A Illian
  • S Neonakis
  • K H Nicolaides
چکیده

OBJECTIVES To investigate whether the addition of maternal serum placental growth factor (PlGF) measured at 19-24 weeks' gestation improves the performance of screening for stillbirth that is achieved by a combination of maternal factors, fetal biometry and uterine artery pulsatility index (UtA-PI) and to evaluate the performance of screening with this model for all stillbirths and those due to impaired placentation and unexplained or other causes. METHODS This was a prospective screening study of 70 003 singleton pregnancies including 268 stillbirths, carried out in two phases. The first phase included prospective measurement of UtA-PI and fetal biometry, which were available in all cases. The second phase included prospective measurement of maternal serum PlGF, which was available for 9870 live births and 86 antepartum stillbirths. The values of PlGF obtained from this screening study were simulated in the remaining cases based on bivariate Gaussian distributions, defined by the mean and standard deviations. Multivariable logistic regression analysis was used to determine whether the addition of maternal serum PlGF improved the performance of screening that was achieved by a combination of maternal factors, fetal biometry and UtA-PI. RESULTS Significant contribution to the prediction of stillbirth was provided by maternal factor-derived a-priori risk, multiples of the median values of PlGF, UtA-PI and fetal biometry Z-scores. A model combining these variables predicted 58% of all stillbirths and 84% of those due to impaired placentation, at a false-positive rate of 10%. Within the impaired-placentation group, the detection rate of stillbirth < 32 weeks' gestation was higher than that of stillbirth ≥ 37 weeks (97% vs 61%; P < 0.01). CONCLUSIONS A high proportion of stillbirths due to impaired placentation can be identified effectively in the second trimester of pregnancy using a combination of maternal factors, fetal biometry, uterine artery Doppler and maternal serum PlGF. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Altered fetal growth, placental abnormalities, and stillbirth

BACKGROUND Worldwide, stillbirth is one of the leading causes of death. Altered fetal growth and placental abnormalities are the strongest and most prevalent known risk factors for stillbirth. The aim of this study was to identify patterns of association between placental abnormalities, fetal growth, and stillbirth. METHODS AND FINDINGS Population-based case-control study of all stillbirths a...

متن کامل

Prediction of stillbirth from placental growth factor at 11-13 weeks.

OBJECTIVES To investigate whether the addition of maternal serum placental growth factor (PlGF) measured at 11-13 weeks' gestation improves the performance of screening for stillbirths that is achieved by a combination of maternal factors and first-trimester biomarkers such as maternal serum pregnancy-associated plasma protein-A (PAPP-A), fetal ductus venosus pulsatility index for veins (DV-PIV...

متن کامل

Abnormalities of the placenta

Normal placental structure and function is essential for a healthy pregnancy; the placenta is responsible for nutrient and oxygen transport, removal of waste products, protection from infection, modulation of the maternal immune system and hormone production to maintain pregnancy. The human placenta is structurally adapted to fulfil this role as it is haemomonochorial, minimising the distance b...

متن کامل

Repeat measurements of uterine artery pulsatility index, mean arterial pressure and serum placental growth factor at 12, 22 and 32 weeks in prediction of pre-eclampsia.

OBJECTIVE To investigate the potential value of repeat measurements of uterine artery pulsatility index (UtA-PI), mean arterial pressure (MAP) and serum placental growth factor (PlGF) at 12, 22 and 32 weeks' gestation in the prediction of pre-eclampsia (PE) developing after 32 weeks. METHODS Data were derived from prospective screening for adverse obstetric outcomes in women attending their r...

متن کامل

Placental Growth Factor in 24 to 30 Weeks of gestation as a predictor of Pre Eclampsia

Background: Pre-eclampsia is one of the leading causes of maternal mortality and is lest understood in aspects of physiology; it awaits sensitive and specific tests for its prediction. Objectives: 1.Placental growth factor is one test that is evolving as a predictor of preeclampsia. Present study aims to evaluate this aspect. 2. To evaluate the value of placental growth factor in predicting the...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology

دوره 48 5  شماره 

صفحات  -

تاریخ انتشار 2016